• Explore /
  • Poster
  • / A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.

A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.

Abstract Poster

Authors

null

Bruno Sangro

Liver Unit, Clinica Universidad de Navarra and CIBERHD, Pamplona, Spain

Bruno Sangro , Joong-Won Park , Christine Marie Dela Cruz , Jeffrey Anderson , Lixin Lang , Jaclyn Neely , James W Shaw , Ann-Lii Cheng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT02576509

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS4147)

DOI

10.1200/JCO.2016.34.15_suppl.TPS4147

Abstract #

TPS4147

Poster Bd #

131a

Abstract Disclosures

Similar Posters

First Author: William Joseph Chapin

First Author: Kohei Shitara

First Author: Arndt Vogel

First Author: Julien Edeline